Navigation Links
Hikma - 2007 Preliminary Results Interviews With CEO and CFO
Date:3/18/2008

LONDON, March 18 /PRNewswire-FirstCall/ -- In video interviews Said Darwazah, CEO, and Bassam Kanaan, CFO, discuss Hikma's 2007 performance, financing and acquisitions, plus what they are expecting from the company in 2008. The interviews, transcripts, podcasts and vodcasts are available now on http://www.cantos.com.

It's free to view. All you need to do is register at http://www.cantos.com. Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives.

If you would like to contact us, please email enquiries@cantos.com or phone +44-207-936-1333.


'/>"/>
SOURCE Hikma Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
3. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
4. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
8. Symmetry Medical Reports Preliminary Third Quarter Revenue
9. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
10. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
11. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):